HPTN 083: Long-Acting Injectable CAB Superior to Daily Oral TDF/FTC as PrEP in MSM and TGW at High Risk of HIV Infection

July 6-10, 2020; Virtual
Long-acting CAB injected intramuscularly every 2 months reduced the risk of HIV infection by 66% compared with daily oral TDF/FTC in high-risk MSM and transgender women.
Format: Microsoft PowerPoint (.ppt)
File Size: 294 KB
Released: July 11, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

Expert-authored CCO slides on strategies encompassed by the Ending the HIV Epidemic Initiative, including prevention and rapid diagnosis and treatment

W. David Hardy, MD
Program Director
David A. Wohl, MD
Released: October 20, 2020

Download CCO slides reviewing data and guidelines on management of heavily-treatment experienced patients with HIV experiencing treatment failure

Joseph J. Eron, Jr., MD Princy N. Kumar, MD, FIDSA, MACP Released: October 20, 2020

Expert-authored CCO slides on simplification to 2-drug ART, ART safety during pregnancy, ART and weight gain, and long-acting injectable ART

W. David Hardy, MD
Program Director
Michelle S. Cespedes, MD, MS
Released: October 20, 2020

CCO slides on ending the HIV epidemic in the United States via expanded testing, enhanced linkage to care, and rapid response to potential outbreaks

Lisa K. Fitzpatrick, MD, MPH, MPA David Malebranche, MD, MPH Released: October 7, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue